Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dosage Regimen: Fixed Dose01:01

Dosage Regimen: Fixed Dose

Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
Dose Size and Dosing Frequency: Determination Methods01:21

Dose Size and Dosing Frequency: Determination Methods

Determining the optimal dose size and dosing frequency in pharmacotherapy is crucial for achieving therapeutic effectiveness while minimizing adverse effects. This article explores the methodologies employed in determining these parameters, focusing on their significance and interplay to tailor dosing regimens.Dose Size: Dose size refers to the amount of a drug administered in a single dose. It is determined based on the drug's pharmacodynamics and pharmacokinetics properties and...
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Advancing Theranostics in Alzheimer Disease: FDA Approval of Amyloid-β PET Drugs for Selection of Patients for Amyloid-β-Directed Therapies and Other Labeling Updates.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

Gastrointestinal Acute Radiation Syndrome: Mechanisms, Models, Markers, and Medical Countermeasures.

Radiation research·2024
Same author

Quantitative Brain Amyloid PET.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2024
Same author

The impact of misclassification errors on the performance of biomarkers based on next-generation sequencing, a simulation study.

Journal of biopharmaceutical statistics·2023
Same author

US FDA public meeting: identification of concepts and terminology for multicomponent biomarkers.

Biomarkers in medicine·2023
Same author

Bayesian Sample Size Planning Tool for Phase I Dose-Finding Trials.

JCO precision oncology·2022

Related Experiment Video

Updated: May 21, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

Sample size adaptation in fixed-dose combination drug trial.

H M James Hung1, Sue-Jane Wang

  • 1Division of Biometrics I, OB/OTS/CDER, U.S. Food and Drug Administration, Silver Spring , MD 20993-0002, USA. hsienming.hung@fda.hhs.gov

Journal of Biopharmaceutical Statistics
|June 2, 2012
PubMed
Summary

Complex statistical testing in clinical trials can be simplified by understanding nuisance parameters. This study explores how sample size reallocation based on nuisance parameter knowledge can improve statistical testing efficiency and power.

More Related Videos

Disposable Dosators Intended for Dry Powder Delivery to Mice
04:59

Disposable Dosators Intended for Dry Powder Delivery to Mice

Published on: August 18, 2023

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

Related Experiment Videos

Last Updated: May 21, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

Disposable Dosators Intended for Dry Powder Delivery to Mice
04:59

Disposable Dosators Intended for Dry Powder Delivery to Mice

Published on: August 18, 2023

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

Area of Science:

  • Biostatistics
  • Clinical Trial Design

Background:

  • Statistical testing in clinical trials faces complexity due to nuisance parameters.
  • Nuisance parameters, especially those linked to the main parameter, can complicate error rate control.

Purpose of the Study:

  • To investigate the impact of nuisance parameter knowledge on clinical trial design.
  • To explore the potential for enhanced statistical testing efficiency through sample size reallocation.

Main Methods:

  • The study examines statistical testing scenarios involving nuisance parameters.
  • It considers the intersection-union test as a relevant example.
  • The research analyzes the effect of knowing the range of a nuisance parameter on trial design.

Main Results:

  • Knowledge of nuisance parameter ranges can inform clinical trial design.
  • Sample size reallocation at interim looks, based on nuisance parameter values, may improve efficiency.
  • Potential power advantages exist from adaptive sample size strategies.

Conclusions:

  • Understanding nuisance parameters is crucial for robust clinical trial statistics.
  • Adaptive designs incorporating nuisance parameter information can optimize trial efficiency and power.